BIRC5 and cancer: As a prognostic factor, survivin expression is significantly associated with poor clinical outcome in cancers such as neuroblastoma, colorectal cancer, breast cancer, lung cancer, esophageal cancer, medulloblastoma, and pediatric acute lymphoblastic leukemia [15–22].